Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive deep into the groundbreaking EV302 study with special guest Dr. Thomas Powles. In this episode, they discuss the approval of Enfortumab and Pembrolizumab as a combination therapy for advanced bladder cancer, based on the remarkable results of the study. Dr. Powles shares insights on the study design, findings, and the transformative impact of the treatment on patients' lives. Discover how this new standard of care in bladder cancer has significantly improved overall survival benefits, with a median survival of 31.5 months compared to 16.1 months with chemotherapy. The discussion also delves into managing the side effects of the treatment and the potential use of ctDNA in monitoring disease progression. Don't miss this informative episode that sheds light on the evolving landscape of bladder cancer treatment and the hope it brings to patients. Stay tuned for a quick recap and insights from the Oncology Brothers.
Oncology Brothers: Practice-Changing Cancer Discussions